Sentara Norfolk General Hospital

The trials here

What the 76 trials at this site are about, from their registry records.

Conditions

• Atrial fibrillation12 trials
• Heart failure12 trials
• Aortic stenosis11 trials
• Coronary artery disease6 trials
• Lung cancer6 trials
• Stroke6 trials
• Deep vein thrombosis and pulmonary embolism5 trials
• Pancreatic cancer5 trials
• Prostate cancer5 trials
• Peripheral artery disease4 trials
• Aortic aneurysm3 trials
• Bladder cancer3 trials
• and 22 more

Phase

• Phase 314 trials
• Phase 23 trials
• Phase 2/32 trials
• Phase 41 trial

Status

• Active, not recruiting29 trials
• Completed23 trials
• Recruiting19 trials
• Suspended2 trials
• Withdrawn2 trials
• Enrolling by invitation1 trial

Lead sponsor

• Abbott Medical Devices11 trials
• National Cancer Institute (NCI)6 trials
• Alliance for Clinical Trials in Oncology5 trials
• Edwards Lifesciences5 trials
• Boston Scientific Corporation4 trials
• and 34 more

Running trials

• Recruiting

  Aspiration Thrombectomy Using the Symphony or Prodigy System

  NCT07350499· Imperative Care, Inc.· Source

  Contact: Sylvie Akiel-Fu, MPH

• Active, not recruiting

  Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)

  NCT07308847· Medtronic Cardiac Ablation Solutions· Source

• Recruiting

  PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis

  NCT06422871· Merit Medical Systems, Inc.· Source

  Contact: Hannah Susmeyer

• Recruiting

  Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

  NCT06909565· Phase 4· Duke University· Source

  Contact: Angela Zahn

• Recruiting

  The Vanguard Study: Testing a New Way to Screen for Cancer

  NCT06995898· National Cancer Institute (NCI)· Source

  Contact: John M. Sayles (principal investigator)

• Recruiting

  Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG

  NCT07087613· Eko Devices, Inc.· Source

  Contact: KIMBERLY MACIAS, MS

• Active, not recruiting

  Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

  NCT06735534· Boston Scientific Corporation· Source

• Active, not recruiting

  ASCEND CSP IDE Study

  NCT06830746· Abbott Medical Devices· Source

• Recruiting

  REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE

  NCT06777368· Medtronic Cardiovascular· Source

  Contact: Christine Calayo

• Recruiting

  DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

  NCT06388421· United Therapeutics· Source

  Contact: Michael Eggert, MD

• Active, not recruiting

  SIMPLAAFY Clinical Trial

  NCT06521463· Boston Scientific Corporation· Source

• Active, not recruiting

  ADVENT Post Approval Study

  NCT06431815· Boston Scientific Corporation· Source

• Active, not recruiting

  A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)

  NCT06455098· Biosense Webster, Inc.· Source

• Recruiting

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

  NCT06424288· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Enrolling by invitation

  ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation

  NCT05932615· Abbott Medical Devices· Source

• Recruiting

  Decellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry

  NCT05880537· LifeNet Health· Source

  Contact: Amanda Anderson

• Recruiting

  DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

  NCT05701917· Inari Medical· Source

  Contact: David J Dexter, MD

• Recruiting

  PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

  NCT05313165· LimFlow, Inc.· Source

  Contact: Sarah Havert

• Active, not recruiting

  Abbott Atrial Fibrillation Post Approval Study

  NCT05434650· Abbott Medical Devices· Source

• Recruiting

  Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  NCT05334069· Alliance for Clinical Trials in Oncology· Source

  Contact: Jennifer Ward (principal investigator)

• Recruiting

  ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve

  NCT05172960· Edwards Lifesciences· Source

  Contact: Edwards THV Clinical Affairs

• Recruiting

  Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

  NCT05102019· Shockwave Medical, Inc.· Source

  Contact: Ashley McQuarter

• Recruiting

  PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR

  NCT04889872· Edwards Lifesciences· Source

  Contact: Edwards THV Clinical Affairs

• Recruiting

  ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES

  NCT04503395· FCRE (Foundation for Cardiovascular Research and Education)· Source

  Contact: Hosam El-Sayed

• Recruiting

  Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk

  NCT04774159· Phase 3· Population Health Research Institute· Source

  Contact: David Dexter

• Active, not recruiting

  TRISCEND II Pivotal Trial

  NCT04482062· Edwards Lifesciences· Source

• Active, not recruiting

  SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial

  NCT04722250· Medtronic Cardiovascular· Source

• Recruiting

  NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness

  NCT04471909· Endospan Ltd.· Source

  Contact: Amanda Anderson

• Active, not recruiting

  Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

  NCT04340141· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Amplatzer Amulet LAAO vs. NOAC

  NCT04226547· Abbott Medical Devices· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

  NCT04239573· ECOG-ACRIN Cancer Research Group· Source

  Contact: Eric C. Feliberti (principal investigator)

• Active, not recruiting

  A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

  NCT04165317· Phase 3· Pfizer· Source

• Active, not recruiting

  Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial

  NCT03947619· Abiomed Inc.· Source

• Active, not recruiting

  SyncAV Post-Market Trial

  NCT04100148· Abbott Medical Devices· Source

• Active, not recruiting

  Portico Next Generation Approval Study

  NCT04011722· Abbott Medical Devices· Source

• Active, not recruiting

  ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement

  NCT03735667· Boston Scientific Corporation· Source

• Active, not recruiting

  A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

  NCT03809000· Phase 2· RTOG Foundation, Inc.· Source

• Active, not recruiting

  Destination Therapy Post Approval Study

  NCT03681210· Medtronic Cardiac Rhythm and Heart Failure· Source

• Active, not recruiting

  Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

  NCT03367702· Phase 3· NRG Oncology· Source

• Active, not recruiting

  AMPLATZER PFO Occluder Post Approval Study

  NCT03309332· Abbott Medical Devices· Source

• Active, not recruiting

  Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial

  NCT02000115· Abbott Medical Devices· Source

• Active, not recruiting

  Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

  NCT01368588· Phase 3· Radiation Therapy Oncology Group· Source

• Active, not recruiting

  Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

  NCT01220583· Phase 2· Radiation Therapy Oncology Group· Source

• Active, not recruiting

  Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

  NCT00499330· Alliance for Clinical Trials in Oncology· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Aortic stenosis4 recruiting
• Coronary artery disease3 recruiting
• Pancreatic cancer3 recruiting
• Aortic aneurysm2 recruiting
• Bladder cancer2 recruiting
• Chronic kidney disease2 recruiting
• Colorectal cancer2 recruiting
• Deep vein thrombosis and pulmonary embolism2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Heart failure2 recruiting
• High blood pressure2 recruiting
• Lung cancer2 recruiting
• Ovarian cancer2 recruiting
• Peripheral artery disease2 recruiting
• Prostate cancer2 recruiting
• Pulmonary arterial hypertension2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukaemia1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Stroke1 recruiting

Closed trials

• Recruiting

  Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

  NCT06736574· Phase 3· Cytokinetics· Source

  Contact: Cytokinetics MD

• Completed

  VOLT-AF IDE Clinical Study

  NCT06223789· Abbott Medical Devices· Source

• Completed

  SYMPHONY-PE Study for Treatment of Pulmonary Embolism

  NCT06062329· Imperative Care, Inc.· Source

• Completed

  A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAF

  NCT06144632· Biosense Webster, Inc.· Source

• Completed

  Comparison of Two Pulmonary Embolism Treatments

  NCT05684796· Penumbra Inc.· Source

• Completed

  RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms

  NCT05595369· Phase 2· Kanecia Obie Zimmerman· Source

• Completed

  Validation of CardioMEMS HF System Cardiac Output Algorithm IDE

  NCT05428384· Abbott Medical Devices· Source

• Completed

  The PEERLESS Study

  NCT05111613· Inari Medical· Source

• Completed

  Treatment of Persistent Atrial Fibrillation With Sphere-9 Catheter and Affera Mapping and Ablation System

  NCT05120193· Medtronic Cardiac Ablation Solutions· Source

• Completed

  Disrupt PAD BTK II Study With the Shockwave Peripheral IVL System

  NCT05007925· Shockwave Medical, Inc.· Source

• Completed

  A Study of Elecsys® Troponin T hs Gen 6 in Participants With Symptoms of Acute Coronary Syndrome

  NCT06734117· Hoffmann-La Roche· Source

• Completed

  Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

  NCT04435626· Phase 3· Bayer· Source

• Completed

  Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart Failure

  NCT04452149· Medtronic Cardiac Rhythm and Heart Failure· Source

• Completed

  Optimize PRO Study

  NCT04091048· Medtronic Cardiovascular· Source

• Completed

  Study of Hepatitis Eradication Receiving Protease Inhibitor Administration

  NCT03886077· Sentara Norfolk General Hospital· Source

• Recruiting

  Medtronic Terminate AF Study

  NCT03546374· Medtronic Cardiac Surgery· Source

  Contact: Stephanie Yong

• Completed

  Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

  NCT03258554· Phase 2/3· National Cancer Institute (NCI)· Source

• Recruiting

  The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR

  NCT03142152· Cardiac Dimensions, Inc.· Source

  Contact: Hank Hauser

• Completed

  The DETOUR 2 Clinical Trial

  NCT03119233· Endologix· Source

• Completed

  AMPLATZER™ Amulet™ LAA Occluder Trial

  NCT02879448· Abbott Medical Devices· Source

• Completed

  MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer

  NCT01805076· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Completed

  PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - S3 Intermediate

  NCT03222128· Edwards Lifesciences· Source

• Completed

  ANCHOR (Aneurysm Treatment Using the Heli-FX™ EndoAnchor™ System Global Registry)

  NCT01534819· Medtronic Cardiovascular· Source

• Completed

  PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk

  NCT01314313· Edwards Lifesciences· Source

• Completed

  Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

  NCT01013649· Phase 3· National Cancer Institute (NCI)· Source